Antinociceptive action of 2-(4-bromobenzoyl)-3-methyl-4,6-dimethoxy benzofuran, a novel xanthoxyline derivative on chemical and thermal models of nociception in mice.

Abstract

The antinociceptive effect of the novel xanthoxyline derivative 2-(4-bromobenzoyl)-3-methyl-4-6-dimethoxy benzofuran) (BMDB), given i.p., p.o., s.c., subplantarly, intrathecally or by i.c.v. routes was assessed in five models of chemical and thermal nociception in mice, namely acetic acid-induced abdominal constriction, formalin and capsaicin-induced licking, hot-plate and tail-flick tests. BMDB given by i.p., s.c., subplantarly or by i.c.v. routes elicited dose-related and long-lasting (4 hr) antinociception, but had no significant effect by p.o. route. At the ID50 level, this compound was about 15- to 100-fold more potent than aspirin and acetaminophen, but it was about 2- to 50-fold less potent than morphine. Its analgesic action was not influenced by naloxone, L-arginine, antagonist of alpha-1 adrenoceptor, prazosin, tau -aminobutyric acid (B) antagonist, phaclofen, after adrenalectomy, but was reversed in part by p-chlorophenylalanine methyl ester. Its analgesic action was not secondary to an anti-inflammatory effect, or was it associated with nonspecific effect such as muscle relaxant or sedative actions of animals. We conclude that BMDB produces dose-dependent spinal and supraspinal antinociception as evaluated in several algesic models in mice, including the neurogenic nociception responses induced by formalin and capsaicin. Its antinociceptive effect was insensitive to naloxone, suggesting the lack of involvement of endogenous opioid, was not modulated by adrenal glands and does not involve interaction with the L-arginine-nitric oxide pathway, activation of alpha-1 adrenoceptors or tau-aminobutyric acidB receptors, but requires, at least in part, the serotoninergic pathway.